Jesús Ruiz-Contreras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesús Ruiz-Contreras has a total of 585 co-authors. Here are the top co-authors by number of shared publications:
- Teresa Hernández-Sampelayo
Sección de Enfermedades Infecciosas Pediátricas, Servicio de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid, Spain
14 shared publications - Luis Ignacio Gonzalez-Granado
Hospital 12 Octubre, Research Institute University Hospital 12 de Octubre Complutense School of Medicine 10 Primary Immunodeficiencies Unit, Department of Pediatrics Madrid
11 shared publications F.J. Álvarez García
9 shared publicationsM. Merino Moína
9 shared publicationsM.J. Cilleruelo Ortega
9 shared publications- Estela Paz-Artal
Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
8 shared publications
Latest Publications
- 30 December 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 574
Vacunas antineumocócicas
Revisión narrativa/descriptiva de la epidemiología de las infecciones neumocócicas en nuestro país, y de las vacunas neumocócicas disponibles y en desarrollo. En la actualidad, 2 de cada 3 casos de enfermedad neumocócica invasiva (ENI) se deben a serotipos no vacunales no contenidos en la vacuna neumocócica conjugada 13-valente. Sin embargo, algunos de los serotipos vacunales, como el 4, el 14, el 3, el 19A y el 19F, se mantienen. El serotipo 3 es el primer causante de ENI tanto en niños como en adultos mayores de 65 años. En los niños menores de 5 años, los serotipos más frecuentes son: 3, 24F, 22F, 8, 15B, 19A, 10A, 15A, 38 y 33F. Algunos serotipos tienen un tropismo especial por algunos órganos y sistemas: el serotipo 3 propende a causar neumonías necrotizantes y empiemas, mientras que los serotipos 24F y 10A tienden a causar meningitis. Las nuevas vacunas neumocócicas conjugadas, la 15-valente y la 20-valente, suponen un avance en el control de la enfermedad neumocócica, aunque no se disponen de estudios de eficacia que permitan estimar el impacto de las mismas. La vacuna 20-valente proporciona una mayor cobertura de serotipo, pero la 15-valente es significativamente más inmunógena, incluso que la vacuna 13-valente, frente al serotipo 3. Existen otras vacunas neumocócicas conjugadas en desarrollo, que incorporan mayor número de serotipos o utilizan diferentes plataformas de conjugación para mejorar la inmunidad.
- 30 December 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 574
Vacunas antineumocócicas
Revisión narrativa/descriptiva de la epidemiología de las infecciones neumocócicas en nuestro país, y de las vacunas neumocócicas disponibles y en desarrollo. En la actualidad, 2 de cada 3 casos de enfermedad neumocócica invasiva (ENI) se deben a serotipos no vacunales no contenidos en la vacuna neumocócica conjugada 13-valente. Sin embargo, algunos de los serotipos vacunales, como el 4, el 14, el 3, el 19A y el 19F, se mantienen. El serotipo 3 es el primer causante de ENI tanto en niños como en adultos mayores de 65 años. En los niños menores de 5 años, los serotipos más frecuentes son: 3, 24F, 22F, 8, 15B, 19A, 10A, 15A, 38 y 33F. Algunos serotipos tienen un tropismo especial por algunos órganos y sistemas: el serotipo 3 propende a causar neumonías necrotizantes y empiemas, mientras que los serotipos 24F y 10A tienden a causar meningitis. Las nuevas vacunas neumocócicas conjugadas, la 15-valente y la 20-valente, suponen un avance en el control de la enfermedad neumocócica, aunque no se disponen de estudios de eficacia que permitan estimar el impacto de las mismas. La vacuna 20-valente proporciona una mayor cobertura de serotipo, pero la 15-valente es significativamente más inmunógena, incluso que la vacuna 13-valente, frente al serotipo 3. Existen otras vacunas neumocócicas conjugadas en desarrollo, que incorporan mayor número de serotipos o utilizan diferentes plataformas de conjugación para mejorar la inmunidad.
- 3 April 2025
- Published by Elsevier in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
- Vol. 43 (4) , 185-187
Thinking like pediatricians to prevent pneumococcal disease in adults
- 3 April 2025
- Published by Elsevier in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
- Vol. 43 (4) , 185-187
Thinking like pediatricians to prevent pneumococcal disease in adults
- Open Access
- 11 November 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (1) , 157-175
Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain
Introduction Immunization is the most effective strategy for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB); however, parents need to weigh the risk–benefit and financial impact of immunizing their children against MenB in the absence of a national immunization program (NIP). This study aimed to explore societal preferences (of parents and pediatricians) regarding the attributes of a MenB vaccine in Spain. Methods A discrete choice experiment (DCE) based on cross-sectional surveys was carried out to determine preferences. A literature review and scientific committee determined the six attributes related to the MenB vaccine included in the DCE: vaccination age, cost, duration, percentage of protection, adverse events probability, and expert/authority recommendation. Data were analyzed using a mixed logit model. Relative importance (RI) of attributes was calculated and compared between parents and pediatricians. Results A total of 278 parents [55.8% female, mean age 40.4 (standard deviation, SD 7.3) years] and 200 pediatricians [73.0% female, mean age 45.8 (SD 12.9) years] answered the DCE. For parents, the highest RI was attributed to vaccine cost, expert/authority recommendation, and percentage of protection (26.4%, 26.1%, and 22.9%, respectively), while for pediatricians the highest RI was assigned to percentage of protection, expert/authority recommendation, and vaccination age (27.2%, 23.7%, and 22.6%, respectively). Significant differences between parents and pediatricians were found in the RI assigned to all attributes (p < 0.001), except for vaccine recommendation. Conclusion In the decision regarding MenB vaccination, cost was a driver in parental decision-making but had a low RI for pediatricians and, conversely, vaccination age was highly valued by pediatricians but was the attribute with least importance for parents. Despite these differences, expert/authority recommendation and percentage of protection were essential criteria for both groups. These results provide relevant information about MenB vaccination, highlighting the importance of considering societal preferences for NIP inclusion. Graphical Abstract
- 11 November 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (1) , 157-175
Open AccessSocietal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain
Introduction Immunization is the most effective strategy for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB); however, parents need to weigh the risk–benefit and financial impact of immunizing their children against MenB in the absence of a national immunization program (NIP). This study aimed to explore societal preferences (of parents and pediatricians) regarding the attributes of a MenB vaccine in Spain. Methods A discrete choice experiment (DCE) based on cross-sectional surveys was carried out to determine preferences. A literature review and scientific committee determined the six attributes related to the MenB vaccine included in the DCE: vaccination age, cost, duration, percentage of protection, adverse events probability, and expert/authority recommendation. Data were analyzed using a mixed logit model. Relative importance (RI) of attributes was calculated and compared between parents and pediatricians. Results A total of 278 parents [55.8% female, mean age 40.4 (standard deviation, SD 7.3) years] and 200 pediatricians [73.0% female, mean age 45.8 (SD 12.9) years] answered the DCE. For parents, the highest RI was attributed to vaccine cost, expert/authority recommendation, and percentage of protection (26.4%, 26.1%, and 22.9%, respectively), while for pediatricians the highest RI was assigned to percentage of protection, expert/authority recommendation, and vaccination age (27.2%, 23.7%, and 22.6%, respectively). Significant differences between parents and pediatricians were found in the RI assigned to all attributes (p < 0.001), except for vaccine recommendation. Conclusion In the decision regarding MenB vaccination, cost was a driver in parental decision-making but had a low RI for pediatricians and, conversely, vaccination age was highly valued by pediatricians but was the attribute with least importance for parents. Despite these differences, expert/authority recommendation and percentage of protection were essential criteria for both groups. These results provide relevant information about MenB vaccination, highlighting the importance of considering societal preferences for NIP inclusion. Graphical Abstract
- Open Access
- 3 January 2022
- Published by Elsevier in Anales de Pediatría
- Vol. 96 (1) , 59.e1-59.e10
Calendario de vacunaciones de la Asociación Española de Pediatría: Recomendaciones 2022
- 3 January 2022
- Published by Elsevier in Anales de Pediatría
- Vol. 96 (1) , 59.e1-59.e10
Open AccessCalendario de vacunaciones de la Asociación Española de Pediatría: Recomendaciones 2022
- Open Access
- 1 January 2021
- Published by Elsevier in Anales de Pediatría
- Vol. 94 (1) , 53.e1-53.e10
Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2021
- 1 January 2021
- Published by Elsevier in Anales de Pediatría
- Vol. 94 (1) , 53.e1-53.e10
Open AccessCalendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2021
- Open Access
- 1 January 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 88 (1) , 53.e1-53.e9
Immunisation schedule of the Spanish Association of Paediatrics: 2018 recommendations
- 1 January 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 88 (1) , 53.e1-53.e9
Open AccessImmunisation schedule of the Spanish Association of Paediatrics: 2018 recommendations
- 31 October 2017
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 7 (2) , 175-176
Effects of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Aged 0 to 90 Days in Madrid, Spain
- 31 October 2017
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 7 (2) , 175-176
Effects of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Aged 0 to 90 Days in Madrid, Spain
- Open Access
- 1 September 2017
- Published by Elsevier in Anales de Pediatría
- Vol. 87 (3) , 181-182
Recomendaciones de la Asociación Española de Pediatría sobre la vacuna neumocócica de 2017. Respuesta de los autores
- 1 September 2017
- Published by Elsevier in Anales de Pediatría
- Vol. 87 (3) , 181-182
Open AccessRecomendaciones de la Asociación Española de Pediatría sobre la vacuna neumocócica de 2017. Respuesta de los autores